🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

17 recruiting trials

for Hepato Cellular Carcinoma (HCC)

PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC) NCT07393074NA1 site📍 Lyon Hospices Civils de Lyon · Tests: Measurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation., Self-administered ques… SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin NCT07560566Phase 21 site📍 Taipei National Taiwan University Hospital · Tests: Topical Indomethacin Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab NCT07276100Phase 21 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna · Tests: Fecal microbiota transplantation (FMT), Atezolizumab & Bevacizumab Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma NCT07536789Phase 21 site📍 Shanghai Fudan University · Tests: MRG003 The Impact of Anaesthesia and Sedation on Inflammation and NETosis in Hepatocellular Carcinoma Ablation NCT07657897NA1 site📍 Cluj-Napoca Iuliu Hatieganu University of Medicine and Pharmacy · Tests: Sedation using combination of Propofol and Fentanyl., Sedation using combination of Propofol and Fentanyl and lidocaine Effect and Mechanism of ALPPS Operation on Liver Regeneration NCT07142213n/a1 site📍 Beijing Haitao Zhao, MD · Tests: ALPPS TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk NCT07487662Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: sintilimab, ipilimumab N01, Lenvatinib, TACE, ablation Hepatocellular Carcinoma Identification Using Delta-HLD NCT07148310n/a1 site📍 Mendoza Epiliquid Holding, Inc A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma NCT07328009Phase 21 site📍 Shanghai Fudan University · Tests: Lenvatinib, Regorafenib (BAY 73-4506), Tislelizumab+TKI, HAIC+TKI, HAIC + Tislelizumab+TKI Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma NCT07302919Phase 2, Phase 33 sites📍 Basel📍 Geneva📍 Sankt Gallen University Hospital, Basel, Switzerland · Tests: DEB-DoxNic-TACE, current standard of care Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma NCT06960863n/a1 site📍 Tanta Tanta University · Tests: fibroscan PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC NCT06742424Phase 21 site📍 Chengdu West China Hospital · Tests: PD-L1 antibody, Bevacizumab, HAIC-FOLFOX HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence NCT06812039Phase 23 sites📍 Fuzhou📍 Shanghai📍 Tianjin Fudan University · Tests: HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) NCT06990659NA19 sites📍 Amiens📍 Angers📍 Besançon University Hospital, Angers · Tests: Ambulatory care, Conventional inpatient care Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC NCT07267806Phase 31 site📍 Guangzhou Linhui Peng · Tests: Infusional mFOLFOX7 plus Camrelizumab and apatinib, Camrelizumab and apatinib IIT2025-03-YANG-LIFT-HCC NCT07489976Phase 21 site📍 Los Angeles Ju Dong Yang · Tests: STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA) PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma NCT06960954n/a1 site📍 Tanta Tanta University · Tests: Prothrombin induced by vitamin K absence II (PIVKA-II)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy